{"contentid": 488476, "importid": NaN, "name": "Pandemic and pricing dent first quarter performance at Amgen", "introduction": "A hugely disappointing first quarter for Amgen saw revenues slide to $5.9 billion, down from $6.2 billion and below most analysts\u00e2\u0080\u0099 expectations.", "content": "<p>A hugely disappointing first quarter for Amgen (Nasdaq: AMGN) saw revenues slide to $5.9 billion, down from $6.2 billion and below most analysts&rsquo; expectations.</p>\n<p>Shares in the company fell 2% on Tuesday, and continued falling a further 3% in after-hours trading.</p>\n<p>Chief executive Robert Bradway explained that the firm&rsquo;s performance was hit by the coronavirus pandemic, with more people staying at home instead of visiting their doctor. March is also traditionally a slow month, the firm said.</p>\n<p>However, with sales volumes on the up, the outcome is largely due to a fall in prices, which saw a net decline of 7%. Revenues for autoimmune blockbuster Enbrel (etanercept) were off 20%, while migraine drug Aimovig (erenumab) saw 7% lower revenues.</p>\n<p>Following Generally Accepted Accounting Principles (GAAP), net income was $1.6 billion, down 10%, with earnings per share (EPS) decreasing 8% to $2.83.</p>\n<p>Staying positive, Mr Bradway said: \"While our business continued to be impacted by the COVID-19 pandemic particularly in the first two months of the quarter, we are encouraged by strong volume trends in many of our newer products and remain confident in the outlook for the full year.\"</p>\n<p>He added: &ldquo;We also continue to advance key pipeline opportunities, including three late-stage assets that have earned Breakthrough Therapy Designation from the US Food and Drug Administration.\"</p>\n<p>While high rates of vaccination in the USA will help patient visits and diagnoses to recover, the firm said it expected to see &ldquo;continuing disruption from COVID-19 in the second quarter and, to a lesser degree, in the second half of the year.&rdquo;</p>\n<p>For the first quarter, demand was most negatively affected in January and February due to a surge of cases in the USA and in Europe, with the situation improving in March and continuing into April.</p>\n<p>Amgen reaffirmed its 2021 total revenue guidance, at $25.8 to $26.6 billion, with EPS guidance revised to between $9.11 and $10.71 on a GAAP basis.</p>\n<h2>Selected product performance</h2>\n<p>Prolia (denosumab) - $758 million, up 16% from $654 million.</p>\n<p>Repatha (evolocumab) - $286 million, up 25% from $229 million.</p>\n<p>Enbrel (etanercept) - $924 million, down 20% from $1.1 billion.</p>\n<p>Kyprolis (carfilzomib) - $251 million, down 10% from $280 million.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-04-28 11:45:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-28 10:38:06", "updated": "2021-04-28 11:51:57", "access": NaN, "url": "https://www.thepharmaletter.com/article/pandemic-and-pricing-dent-first-quarter-performance-at-amgen", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "amgen_big.jpg", "image2id": "amgen_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Autoimmune Disorders, Oncology", "topic_tag": "Financial, Management", "geography_tag": "USA", "company_tag": "Amgen", "drug_tag": "Aimovig, Enbrel, Kyprolis, Prolia, Repatha", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-28 11:45:00"}